Peter L. Saltonstall Tribute - 2024 NORD Rare Impact Awards

(6:14)

Rare Disease Advocacy: KGI President Sheldon Schuster Interviews NORD CEO Peter Saltonstall

(30:42)

Peter Saltonstall of NORD on Drug Pricing Challenges

(2:59)

Peter Saltonstall Discusses the Orphan Drug Act

(1:15)

A Heartfelt Thank You From Peter L. Saltonstall

(43)

What the Future Looks Like for the Rare Disease Patient

(3:27)

Peter Saltonstall: NORD's Focus on the Rare Disease Patient

(5:27)

Peter Saltonstall: Our Payor System for Drugs Needs to Be Updated

(3:16)

NORD CEO, Peter Saltonstall, Welcoming Remarks

(2:55)

Barry and Mo

(1:4:14)

The Great WWI Controversy: Who Was to Blame? A Panel Discussion on the Centennial

(1:45:49)

Banner Years: The Official History of the Boston Garden

(1:21:16)

Peter Schjeldahl - AICA-USA Distinguished Critic Lecture | The New School

(1:1:33)

Origins: Orphan Genes Puzzle

(26:31)

Vanderbilt's Biltmore Estate: 6 Years to Build, 43 Bathrooms 🤩 Aerial America | Smithsonian Channel

(3:22)

Advanced Topics in Patent Law: Patent and FDA Strategies for New Drugs

(1:5)

Steven Pinker on Violence

(1:47:42)

A Conversation on the Federal Funding Landscape for Citizen Science- March 2023

(1:29:46)

Heptonstall, West Yorkshire【4K】| Village Centre Walk 2021

(23:15)

NORD’s Rare Summit 2020 Goes Virtual

(1:23)

2020 Living Rare, Living Stronger | NORD Patient \u0026 Family Forum | Announcement

(25)

1 in 10 Americans are impacted by rare diseases 'it's a significant number', says NORD's Saltonstall

(4:41)

Rare Disease Day 2023 and NORD

(3:31)

NORD President Introduces FDA Webinars

(43)

DIA \u0026 NORD Leadership Welcome Remarks to US Conference on Rare Diseases \u0026 Orphan Products

(11:)

Rare Diseases: The Path Less Chosen - Boston Children's Hospital | Innovation Summit 2014

(51:59)

Ride for Heart Health Interview with Peter Saltonstall

(23:44)

Technology offers new tools, challenges for rare disease patients

(7:53)

NORD's Centers of Excellence

(3:4)

Orphan Drug Development, Pricing, and Access

(2:34)